FDA accepted the BLA filing for Tab-cel from Atara Biotherapeutics on July 24, 2025.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA accepted the BLA filing for Tab-cel from Atara Biotherapeutics on July 24, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Atara Biotherapeutics, Inc.
clinical-stage biotechnology company
Nothing else this week.
Related events
- Mesoblast is seeking FDA review of the BLA for its product rexlemestrocel-L.
- FDA issued a Complete Response Letter (CRL) regarding Disc Medicine, Inc.'s bitopertin program.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
Coverage
Newest first; wire copies grouped- Business WireAtara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transpla